Titlebook: Kooperativer Führungsstil und Organisation; Zur Leistungsf?higke Günter Zepf Book 1972 Springer Fachmedien Wiesbaden 1972 Betriebswirtschaf

ominous

書目名稱Kooperativer Führungsstil und Organisation影響因子(影響力)




書目名稱Kooperativer Führungsstil und Organisation影響因子(影響力)學科排名




書目名稱Kooperativer Führungsstil und Organisation網(wǎng)絡(luò)公開度




書目名稱Kooperativer Führungsstil und Organisation網(wǎng)絡(luò)公開度學科排名




書目名稱Kooperativer Führungsstil und Organisation被引頻次




書目名稱Kooperativer Führungsstil und Organisation被引頻次學科排名




書目名稱Kooperativer Führungsstil und Organisation年度引用




書目名稱Kooperativer Führungsstil und Organisation年度引用學科排名




書目名稱Kooperativer Führungsstil und Organisation讀者反饋




書目名稱Kooperativer Führungsstil und Organisation讀者反饋學科排名

連鎖,連串

outset

Günter Zepfed for the treatment of genotype 1 HCV infection. The research and development team at Abbott/AbbVie based their approach to HCV cure on the use of three DAAs to avoid emergence of resistance, anchored by a potent protease inhibitor and NS5A inhibitor. Clinical trials were designed to answer multipl

Fillet,Filet

institute

AFFIX

Günter Zepfipasvir and the nonstructural 5B protein (NS5B) nucleotide inhibitor sofosbuvir (SOF), provided a major advancement in the treatment of individuals with chronic genotype 1 (GT1) HCV infection. Herein is described the discovery of velpatasvir (VEL, GS-5816), a pan-genotypic NS5A inhibitor with low pi

偏離

Günter Zepfe advanced liver disease. This has resulted in a reduced incidence of liver cancers and reduced liver-related mortality. Benefits of cure in patients without cirrhosis have not been seen yet in systemic review, but are likely to be seen in the future years. There remain unresolved issues regarding p

外貌

指數(shù)

Günter Zepft to understand basic HCV biology, which led to the development of HCV cell culture systems eventually enabling drug discovery. Initial studies focused on biochemical characterization of viral proteins and dissected their roles in the virus life cycle. Two of the viral proteins, NS3-4A protease and

Vulnerable